Transparent and Relevant Evaluations of Value: An Active Role for Pharma
Published: | Updated:
The biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.
